Pages that link to "Q90749396"
Jump to navigation
Jump to search
The following pages link to Bernard H.E. Jansen (Q90749396):
Displaying 37 items.
- Effects of betulinic acid alone and in combination with irradiation in human melanoma cells (Q28142323) (← links)
- Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound (Q33421041) (← links)
- Novel Ras antagonist blocks human melanoma growth (Q34505870) (← links)
- Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans (Q35129720) (← links)
- What Should Junior Doctors Know about the Drugs they Frequently Prescribe? A Delphi Study among Physicians in the Netherlands (Q38949424) (← links)
- Chemosensitisation of malignant melanoma by BCL2 antisense therapy (Q40611574) (← links)
- Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage. (Q42812141) (← links)
- Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma. (Q43763256) (← links)
- Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice (Q48189982) (← links)
- Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. (Q54948216) (← links)
- Differential expression levels of Par-4 in melanoma (Q59296607) (← links)
- N-ras oncogene expression changes the growth characteristics of human melanoma in two independent SCID-hu mouse models (Q71574509) (← links)
- Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice (Q73035578) (← links)
- bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice (Q74165698) (← links)
- MART-1/Melan-A and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression (Q74609833) (← links)
- Local staging with multiparametric MRI in daily clinical practice: diagnostic accuracy and evaluation of a radiologic learning curve (Q88431867) (← links)
- Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy (Q89843815) (← links)
- Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer (Q89997357) (← links)
- Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging? (Q90593403) (← links)
- Essential diseases in prescribing: A national Delphi study towards a core curriculum in pharmacotherapy education (Q90749404) (← links)
- Letter to the Editor re: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake (Q90785910) (← links)
- Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone (Q90989084) (← links)
- Correction to: Letter to the Editor re: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake (Q92456805) (← links)
- Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer (Q92563027) (← links)
- Reply: Quantification of 18F-DCFPyL Uptake: TBR Versus Patlak's Analysis (Q92880922) (← links)
- Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer (Q92963189) (← links)
- Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer (Q93086215) (← links)
- Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer (Q98184474) (← links)
- Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial (Q98396285) (← links)
- Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer (Q100457194) (← links)
- Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial (Q100739031) (← links)
- PSMA PET/CT in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer (Q102149092) (← links)
- (Q126355162) (← links)
- Early lesion detection with 18F-PSMA (DCFPyL) PET/CT in 248 patients with biochemically recurrent prostate cancer (Q126792834) (← links)
- Verification of 18F-Prostate-Specific Membrane Antigen PET/CT detected lesions - A systematic assessment of the positive predictive value in patients with biochemically recurrent prostate cancer (Q126797457) (← links)
- The Phoenix criteria for biochemically recurrent prostate cancer after curative radiotherapy appear obsolete in the era of prostate-specific membrane antigen PET: A plea for urgent re-evaluation of current guidelines (Q126797471) (← links)
- Preoperative multiparametric MRI does not lower positive surgical margin rate in a large series of patients undergoing robot-assisted radical prostatectomy (Q130524481) (← links)